{"id":"suvorexant-low-dose-ld","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Abnormal dreams"},{"rate":null,"effect":"Worsening insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Suvorexant selectively antagonizes orexin receptors OX1R and OX2R, which are neuropeptide receptors involved in maintaining wakefulness and arousal. By blocking these receptors, the drug reduces the activity of wake-promoting neurons, thereby facilitating sleep onset and maintenance. The low-dose formulation is designed to provide efficacy with potentially reduced side effects compared to standard dosing.","oneSentence":"Suvorexant is an orexin receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:03.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and sleep maintenance)"}]},"trialDetails":[{"nctId":"NCT01097629","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-03","conditions":"Primary Insomnia","enrollment":1020},{"nctId":"NCT01097616","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-05","conditions":"Primary Insomnia","enrollment":1023}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-4305"],"phase":"phase_3","status":"active","brandName":"Suvorexant Low Dose (LD)","genericName":"Suvorexant Low Dose (LD)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Suvorexant Low Dose is a small molecule that acts as an orexin receptor antagonist, a class of drugs that work by blocking the action of orexin receptors. It is being studied as a potential treatment for primary insomnia in a Phase III clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}